Robalzotan (1-100 μg/kg; i.v.) significantly increases the activity of such neurons at 5 μg/kg in rats, and reverses the acute inhibitory effect of citalopram (HY-121203) (300 μg/kg i.v.) or paroxetine (HY-122272) (100 μg/kg, i.v.) on the activity of 5-HT neurons in the dorsal raphe nucleus in rats[1].
Robalzotan (5, 50 μg/kg; i.v.) increases the firing rate of the 5-HT cells[1].
Robalzotan (2-100 μg/kg; i.v.) occupies 5-HT1A receptors in a dose-dependent in monkeys[2].
Robalzotan (0.3; 1 and 3 μmol/kg s.c) causes a dose-dependent increase of extracellular ACh levels in the rat FC[3].
